当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation.

Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation.

Abstract：

:Both conventional chimerism analysis (CCA) and lineage-specific chimerism analysis (LCA) have potential pitfalls as diagnostic means for the detection of minimal residual disease after allogeneic hematopoietic cell transplantation (aHCT). Therefore, the present study examines the results of both methods in order to determine how predictive consecutive evaluations were, with respect to the risk that the patient would relapse during post-transplant follow-up and with respect to responsiveness to immunomodulatory treatment. A total of 168 individuals with acute myeloid leukemia (AML) (n = 137) and myelo dysplastic syndrome (n = 31) were investigated with CCA and LCA at mean intervals of 24 days (range: 11-116). The median follow-up after myeloablative aHCT was 22 months (range: 4-49). Of 168 patients, 65 experienced a clinical relapse after aHCT. CCA and LCA were comparatively sensitive and specific for relapse at the intervals of chimerism testing employed in this study. Of 32 patients, 10 who were offered donor lymphocyte infusions (DLI) treatment for increasing (n = 29) or stable (n = 3) mixed chimerism (MC) achieved at least transitory CC. The observation that all patients with increasing MC relapsed despite DLI treatment (54%) or withdrawal of immune suppression (24%) indicates that novel strategies to deal with rapidly evolving relapse in AML patients, such as shortening of chimerism monitoring intervals, need to be evaluated.

journal_name

Leukemia

journal_title

Leukemia

authors

Zeiser R,Spyridonidis A,Wäsch R,Ihorst G,Grüllich C,Bertz H,Finke J

doi

10.1038/sj.leu.2403719

subject

Has Abstract

pub_date

2005-05-01 00:00:00

pages

814-21

issue

5

eissn

0887-6924

issn

1476-5551

pii

2403719

journal_volume

19

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.

    abstract：:The fusion transcript AML1/ETO corresponding to translocation t(8;21)(q22;q22) can be found in approximately 7-12% of childhood de novo AML. Despite the favorable prognosis, some of these patients relapse. Most of MRD studies so far were performed on adults treated not uniformly. Therefore, we analyzed the follow-up o...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.leu.2402959

    authors： Viehmann S,Teigler-Schlegel A,Bruch J,Langebrake C,Reinhardt D,Harbott J

    更新日期：2003-06-01 00:00:00

  • VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.

    abstract：:Bortezomib (V) was combined with thalidomide (T) and dexamethasone (D) in a phase I/II trial to determine dose-limiting toxicities (DLT's) and clinical activity of the VTD regimen in 85 patients with advanced and refractory myeloma. The starting dose of V was 1.0 mg/m(2) (days 1, 4, 8, 11, every 21 day) with T added f...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.99

    authors： Pineda-Roman M,Zangari M,van Rhee F,Anaissie E,Szymonifka J,Hoering A,Petty N,Crowley J,Shaughnessy J,Epstein J,Barlogie B

    更新日期：2008-07-01 00:00:00

  • Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.

    abstract：:Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse. We presently report the results of a trial of mitoxantrone in combination with cytosine arabinoside (ara-C) in patients with refractory or relapsed acute myelocytic leukemia (AML). Fo...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Paciucci PA,Dutcher JP,Cuttner J,Strauman JJ,Wiernik PH,Holland JF

    更新日期：1987-07-01 00:00:00

  • Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

    abstract：:Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Crucial questions in clinical decision-making include the definition of optimal timing of the procedure and the ben...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.88

    authors： Della Porta MG,Jackson CH,Alessandrino EP,Rossi M,Bacigalupo A,van Lint MT,Bernardi M,Allione B,Bosi A,Guidi S,Santini V,Malcovati L,Ubezio M,Milanesi C,Todisco E,Voso MT,Musto P,Onida F,Iori AP,Cerretti R,Grillo

    更新日期：2017-11-01 00:00:00

  • Osteoclast precursors circulate in the peripheral blood of patients with aggressive multiple myeloma.

    abstract：:Osteolysis resulting in extensive bone damage is a major clinical manifestation of patients with multiple myeloma (MM). The mechanisms of bone resorption in MM are incompletely understood. The final pathway is the generation of activated osteoclasts within bone marrow (BM) microenvironment. To investigate the mechanis...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Gregoretti MG,Bergui L,Aragno M,Cremona O,Marchisio PC,Caligaris-Cappio F

    更新日期：1995-08-01 00:00:00

  • Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.

    abstract：:The AML1/ETO fusion transcript can be detected by reverse transcription polymerase chain reaction (RT-PCR) in patients with t(8;21)-associated acute myeloid leukemia (AML) in long-term complete remission (CR). Quantitation of the amount of the fusion transcript during CR may therefore be more predictive of cure or rel...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401128

    authors： Marcucci G,Livak KJ,Bi W,Strout MP,Bloomfield CD,Caligiuri MA

    更新日期：1998-09-01 00:00:00

  • Chloroquine induces basophilic differentiation of HL-60 cells.

    abstract：:Many agents have been known to induce the differentiation of HL-60 cells. However, only a small number of reports on the basophilic differentiation of this cell line are known. In this study we show that the exposure of HL-60 cells to chloroquine induces to differentiate into basophils. This chloroquine-induced change...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Sasaki R,Furukawa Y,Okada K,Nakamura M,Yamane Y,Miura Y,Eguchi M

    更新日期：1997-04-01 00:00:00

  • Idarubicin DNA intercalation is reduced by MRP1 and not Pgp.

    abstract：:Currently available data regarding the substrate specificity of the multi-drug resistance (MDR) mechanisms P-glycoprotein (Pgp) and MDR-associated protein (MRP1) for idarubicin are inconclusive. A multiparameter flow cytometry method was developed which allows simultaneous quantitative measurement of total cellular fl...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401496

    authors： Smeets ME,Raymakers RA,Vierwinden G,Pennings AH,Boezeman J,Minderman H,de Witte TM

    更新日期：1999-09-01 00:00:00

  • Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report.

    abstract：:One-hundred, twenty-eight patients with Hodgkin's disease in remission or who had failed a mechlorethamine, vincristine, procarbazine and prednisone (MOPP), a doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and/or lomustine, etoposide and prednimustine (CEP) regimens have been treated with a high-dose thera...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Carella Am,Carlier P,Congiu A,Occhini D,Meloni G,Anselmo AP,Mandelli F,Mazza P,Tura S,Mangoni L

    更新日期：1991-01-01 00:00:00

  • Cell death beyond apoptosis.

    abstract：:Though the term apoptosis was originated in pathology and developmental biology as an alternative to necrosis, the tissue necrosis with inflammation is irrelevant to cell culture conditions where apoptosis is mostly studied. Furthermore, no one single morphological feature is either necessary or sufficient to define a...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2401864

    authors： Blagosklonny MV

    更新日期：2000-08-01 00:00:00

  • Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.

    abstract：:Lovastatin is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the major regulatory enzyme of the mevalonate pathway. We have previously reported that lovastatin induces a significant apoptotic response in human acute myeloid leukemia (AML) cells. To identify the critical biochemic...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402196

    authors： Xia Z,Tan MM,Wong WW,Dimitroulakos J,Minden MD,Penn LZ

    更新日期：2001-09-01 00:00:00

  • Ethnic and geographic diversity of chronic lymphocytic leukaemia.

    abstract：:East Asians, Asian Indians and Amerindians have a five to ten-fold lower age-adjusted incidence rate (AAIR) of chronic lymphocytic leukaemia (CLL) compared with persons of predominately European descent. The data we review suggest a genetic rather than environmental basis for this discordance. All these populations ar...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-01057-5

    authors： Yang S,Varghese AM,Sood N,Chiattone C,Akinola NO,Huang X,Gale RP

    更新日期：2020-10-19 00:00:00

  • High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.

    abstract：:Acute myeloid leukemia (AML) is an aggressive malignancy, and development of new treatments to prolong remissions is warranted. Chimeric antigen receptor (CAR) T-cell therapies appear promising but on-target, off-tumor recognition of antigen in healthy tissues remains a concern. Here we isolated a high-affinity (HA) f...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.35

    authors： Lynn RC,Feng Y,Schutsky K,Poussin M,Kalota A,Dimitrov DS,Powell DJ Jr

    更新日期：2016-06-01 00:00:00

  • Rapid amplification of immunoglobulin heavy chain switch (IGHS) translocation breakpoints using long-distance inverse PCR.

    abstract：:Molecular cloning of immunoglobulin heavy chain (IGH) translocation breakpoints identifies genes of biological importance in the development of normal and malignant B cells. Long-distance inverse PCR (LDI-PCR) was first applied to amplification of IGH gene translocations targeted to the joining (IGHJ) regions. We repo...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403500

    authors： Sonoki T,Willis TG,Oscier DG,Karran EL,Siebert R,Dyer MJ

    更新日期：2004-12-01 00:00:00

  • Expression of the CEA gene family members NCA-50/90 and NCA-160 (CD66) in childhood acute lymphoblastic leukemias (ALLs) and in cell lines of B-cell origin.

    abstract：:The carcinoembryonic antigen (CEA) and the classical non-specific cross-reacting antigens (NCAs) belong to the CEA gene family which is part of the immunoglobulin superfamily. In normal hematopoiesis, CEA gene family members (CGMs) have only been reported on cells of myeloid and monocytic origin. In the present study,...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Hanenberg H,Baumann M,Quentin I,Nagel G,Grosse-Wilde H,von Kleist S,Göbel U,Burdach S,Grunert F

    更新日期：1994-12-01 00:00:00

  • HTLV-1 uveitis (HU).

    abstract：:We reported HTLV-1 uveitis (HU) as the third distinct clinical entity associated with HTLV-1 infection. Uveitis has advantages for studying the pathogenetic mechanisms of inflammatory diseases caused by HTLV-1, since observation of the disease process is relatively easy and clinical samples from the lesion can be obta...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Watanabe T,Mochizuki M,Yamaguchi K

    更新日期：1997-04-01 00:00:00

  • An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

    abstract：:The concept of arming antibodies with bioactive payloads for a site-specific therapy of cancer has gained considerable interest in recent years. However, a successful antibody-based targeting approach critically relies on the availability of a tumor-associated target that is not only preferentially expressed in the tu...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.208

    authors： Angenendt L,Reuter S,Kentrup D,Benk AS,Neumann F,Hüve J,Martens AC,Schwöppe C,Kessler T,Schmidt LH,Sauer T,Brand C,Mikesch JH,Lenz G,Mesters RM,Müller-Tidow C,Hartmann W,Wardelmann E,Neri D,Berdel WE,Roesli C,Sc

    更新日期：2018-02-01 00:00:00

  • Spontaneous responsiveness to cytokines by human T-cell leukemias.

    abstract：:The molecular basis for autonomous growth of malignant forms of human T lymphocytes is not known. It can be investigated by functional responses of malignant cells in comparison with untransformed counterparts. At least two pathways (the CD2 and CD3 pathways) of human T-cell activation have been recently defined on th...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Schirren CA,Völpel H,Meuer SC

    更新日期：1992-06-01 00:00:00

  • Unexpected heterogeneity of PML/RAR alpha fused mRNA detected by nested polymerase chain reaction in acute promyelocytic leukemia.

    abstract：:We have analyzed ten APL patients using reverse transcription polymerase chain reaction (RT-PCR) technique to detect PML/RAR alpha fused mRNA. All patients in this study had PML/RAR alpha fused mRNA (three cases of the short type and seven cases of the long type), although the chromosomal translocation t(15;17) was no...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Matsuoka A,Miyamura K,Emi N,Tahara T,Tanimoto M,Naoe T,Ohno R,Kakizuka A,Evans RM,Saito H

    更新日期：1993-08-01 00:00:00

  • Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.

    abstract：:Natural killer (NK) cells are the first lymphocytes to recover after allogeneic stem cell transplantation (SCT) and can exert powerful graft-versus-leukemia (GVL) effects determining transplant outcome. Conditions governing NK cell alloreactivity and the role of NK recovery in sibling SCT are not well defined. NK cell...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404892

    authors： Savani BN,Mielke S,Adams S,Uribe M,Rezvani K,Yong AS,Zeilah J,Kurlander R,Srinivasan R,Childs R,Hensel N,Barrett AJ

    更新日期：2007-10-01 00:00:00

  • Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms.

    abstract：:The unbalanced translocation, der(1;7)(q10;p10), is one of the characteristic cytogenetic abnormalities found in myelodysplastic syndromes (MDS) and other myeloid neoplasms. Although described frequently with very poor clinical outcome and possible relationship with monosomy 7 or 7q- (-7/7q-), this recurrent cytogenet...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404619

    authors： Sanada M,Uike N,Ohyashiki K,Ozawa K,Lili W,Hangaishi A,Kanda Y,Chiba S,Kurokawa M,Omine M,Mitani K,Ogawa S

    更新日期：2007-05-01 00:00:00

  • Therapeutic strategies for postremission treatment in childhood acute myeloid leukemia (AML). The AIEOP experience 1987-1991.

    abstract：:From 1987 to 1990, intensive postremission chemotherapy was compared to autologous bone marrow transplant in previously untreated children with AML who received identical induction therapy with two courses of Daunorubicin (DNR) and conventional dose ARA-C (protocol AIEOP LAM 87). Overall, 121 of the 155 eligible patie...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Amadori S,Giona F,Giuliano M,Moleti ML,Pession A,Rolla M,Rondelli R,Testi AM,Mandelli F

    更新日期：1992-01-01 00:00:00

  • Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.

    abstract：:Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here, we show that trichostatin A, romidepsin and panobinostat induce apoptos...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.357

    authors： Ding H,Peterson KL,Correia C,Koh B,Schneider PA,Nowakowski GS,Kaufmann SH

    更新日期：2017-07-01 00:00:00

  • Modulation of cell surface protein expression by infection with HIV-1.

    abstract：:The examples discussed above show the profound influence of HIV infection on expression pattern of cell surface proteins and the functional relevance thereof. Altered cell surface pattern is involved in all aspects of HIV-induced pathogenesis such as viral spreading viral adhesion and cellular apoptosis and is an impo...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2401322

    authors： Speth C,Dierich MP

    更新日期：1999-04-01 00:00:00

  • Therapeutic targeting of CK2 in acute and chronic leukemias.

    abstract：:CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy explains the involvement of CK2 in many cellular events. However, its predominant roles are stimulation of cell growth and prevention of apoptosi...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2017.301

    authors： Buontempo F,McCubrey JA,Orsini E,Ruzzene M,Cappellini A,Lonetti A,Evangelisti C,Chiarini F,Evangelisti C,Barata JT,Martelli AM

    更新日期：2018-01-01 00:00:00

  • Interleukin-2 and antibody to the T cell receptor regulate proliferation of a radiation leukemia virus-transformed T cell lymphoma.

    abstract：:In this report, a Radiation leukemia virus-transformed murine T cell lymphoma is described which is dependent on the interleukin-2 (IL-2) growth factor for proliferation under single cell conditions of growth. It was isolated from a C57BL mouse which had been primed with the Radiation leukemia virus-induced thymoma, C...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： O'Neill HC

    更新日期：1988-02-01 00:00:00

  • MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

    abstract：:MK-0457, an Aurora kinase and BCR-ABL inhibitor, was studied on a Phase I/II study in 77 patients with refractory hematologic malignancies. The average number of cycles per patient was 3 (range 1-21). Maximum tolerated doses for a 5-day short infusion and continuous infusion regimens were 40 mg/m(2)/h and 144 mg/m(2)/...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.186

    authors： Giles FJ,Swords RT,Nagler A,Hochhaus A,Ottmann OG,Rizzieri DA,Talpaz M,Clark J,Watson P,Xiao A,Zhao B,Bergstrom D,Le Coutre PD,Freedman SJ,Cortes JE

    更新日期：2013-01-01 00:00:00

  • Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

    abstract：:In this phase I/II trial, a triplet regimen of ixazomib (Ixa: 3 or 4 mg), pomalidomide (Pom: 4 mg), and dexamethasone (Dex: 40 mg) was administered to 32 lenalidomide-refractory multiple myeloma (MM) patients; 31 were evaluable for response and toxicity. At dose level 1 (DL1, 3 mg Ixa), 1/3 patients experienced grade ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0038-8

    authors： Krishnan A,Kapoor P,Palmer JM,Tsai NC,Kumar S,Lonial S,Htut M,Karanes C,Nathwani N,Rosenzweig M,Sahebi F,Somlo G,Duarte L,Sanchez JF,Auclair D,Forman SJ,Berdeja JG

    更新日期：2018-07-01 00:00:00

  • Correction: Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study.

    abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title：Leukemia

    pub_type： 已发布勘误

    doi：10.1038/s41375-020-0821-1

    authors： Thastrup M,Marquart HV,Levinsen M,Grell K,Abrahamsson J,Albertsen BK,Frandsen TL,Harila-Saari A,Lähteenmäki PM,Niinimäki R,Pronk CJ,Ulvmoen A,Vaitkevičienė G,Taskinen M,Schmiegelow K,Nordic Society of Pediatric Hematology a

    更新日期：2020-10-01 00:00:00

  • Disruption of the BCL11B gene through inv(14)(q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALL.

    abstract：:T-cell acute lymphoblastic leukemia (T-ALL) is associated with chromosomal aberrations characterized by juxtaposition of proto-oncogenes to T-cell receptor gene loci (TCR), resulting in the deregulated transcription of these proto-oncogenes. Here, we describe the molecular characterization of a novel chromosomal aberr...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403619

    authors： Przybylski GK,Dik WA,Wanzeck J,Grabarczyk P,Majunke S,Martin-Subero JI,Siebert R,Dölken G,Ludwig WD,Verhaaf B,van Dongen JJ,Schmidt CA,Langerak AW

    更新日期：2005-02-01 00:00:00